Zentalis Pharmaceuticals LlcZNTL

ZNTL current price
$3.13-78.94%

Capital at risk.

1W
-15.41%
1M
-24.03%
3M
-16.03%
6M
-63.17%
1Y
-78.94%
MAX
-86.68%
About Zentalis Pharmaceuticals Llc
Ticker
info
ZNTL
Trading on
info
NASDAQ
ISIN
info
US98943L1070
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Julie M. Eastland M.B.A.
Headquarters
info
1359 Broadway, New York, NY, United States, 10018
Employees
info
124
Website
info
https://zentalis.com
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
Metrics
BasicAdvanced
Market cap
info
$249M
P/E ratio
info
-
EPS
info
-$2.24
Dividend Yield
info
0.00%
Beta
info
1.74
Forward P/E ratio
info
0
EBIDTA
info
$-208M
Ex dividend date
info
-
Price & volume
Market cap
info
$249M
Average daily volume
info
1M
90-day return
info
-16.03%
30-day return
info
-24.03%
7-day return
info
-15.41%
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
6.15
Price to book
info
0.7
Earnings
EPS
info
-$2.24
EPS estimate (current quarter)
info
-$0.91
EPS estimate (next quarter)
info
-$0.97
EBITDA
info
$-208M
Revenues (TTM)
info
$40.6M
Revenues per share (TTM)
info
$0.57
Technicals
Beta
info
1.74
52-week High
info
$18.07
52-week Low
info
$2.66
50-day moving average
info
$3.33
200-day moving average
info
$7.13
Short ratio
info
3.17
Short %
info
13.19%
Management effectiveness
ROE (TTM)
info
42.89%
ROA (TTM)
info
25.24%
Profit margin
info
0.00%
Gross profit margin
info
$0M
Operating margin
info
515.94%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
71.3M
Float
info
51.1M
Insiders %
info
9.45%
Institutions %
info
98.05%
Analyst Insights & forecasts
info

46% Buy

54% Hold

0% Sell

Based on information from 11 analysts.

Average price target

info
$9.50
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.93
-$0.92
1.09%
Q4 • 23Beat
$0.14
-$0.77
118.18%
Q1 • 24Beat
-$1.24
-$0.84
47.62%
Q2 • 24Beat
-$0.56
-$0.87
35.69%
Q3 • 24Beat
-
-
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$-88.3M
∞%
Q2 • 24
$0M
$-40.2M
∞%
Q3 • 24
NaN%
54.51%
NaN%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$492M
$109M
22.19%
Q2 • 24
$451M
$96.3M
21.38%
Q3 • 24
8.34%
11.70%
3.67%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-35.1M
$34.5M
$0M
$-35.3M
Q2 • 24
$-44M
$48.2M
$0.1M
$-44M
Q3 • 24
25.35%
39.88%
922.22%
24.70%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Zentalis Pharmaceuticals Llc share?
Collapse

Zentalis Pharmaceuticals Llc shares are currently traded for $3.13 per share.

How many shares does Zentalis Pharmaceuticals Llc have?
Collapse

Zentalis Pharmaceuticals Llc currently has 71.3M shares.

Does Zentalis Pharmaceuticals Llc pay dividends?
Collapse

No, Zentalis Pharmaceuticals Llc doesn't pay dividends.

What is Zentalis Pharmaceuticals Llc 52 week high?
Collapse

Zentalis Pharmaceuticals Llc 52 week high is $18.07.

What is Zentalis Pharmaceuticals Llc 52 week low?
Collapse

Zentalis Pharmaceuticals Llc 52 week low is $2.66.

What is the 200-day moving average of Zentalis Pharmaceuticals Llc?
Collapse

Zentalis Pharmaceuticals Llc 200-day moving average is $7.13.

Who is Zentalis Pharmaceuticals Llc CEO?
Collapse

The CEO of Zentalis Pharmaceuticals Llc is Julie M. Eastland M.B.A..

How many employees Zentalis Pharmaceuticals Llc has?
Collapse

Zentalis Pharmaceuticals Llc has 124 employees.

What is the market cap of Zentalis Pharmaceuticals Llc?
Collapse

The market cap of Zentalis Pharmaceuticals Llc is $249M.

What is the P/E of Zentalis Pharmaceuticals Llc?
Collapse

The current P/E of Zentalis Pharmaceuticals Llc is null.

What is the EPS of Zentalis Pharmaceuticals Llc?
Collapse

The EPS of Zentalis Pharmaceuticals Llc is -$2.24.

What is the PEG Ratio of Zentalis Pharmaceuticals Llc?
Collapse

The PEG Ration of Zentalis Pharmaceuticals Llc is null.

What do analysts say about Zentalis Pharmaceuticals Llc?
Collapse

According to the analysts Zentalis Pharmaceuticals Llc is considered a hold.

Zentalis Pharmaceuticals Llc news